ERBB2 targeted therapies are widely used to treat breast cancer and are being investigated for use in CRC, and there are multiple trials investigating the efficacy of ERBB2-targeted therapies in metastatic CRC [135,145,146,147]. This evidence concerns the gene ERBB2 and colorectal carcinoma.